touchREV Endocrinol, 18(1), 10-19
If any of these are severe or will not go away, call your healthcare provider right away
While the safety of GLP-1 drugs in people with lupus is still under study, there are several potential benefits that could make them an appealing option for those with coexisting conditions, such as diabetes or obesity
The dominant clinical question is whether these benefits are downstream consequences of weight loss, glycemic improvement, and blood-pressure reduction, or whether they reflect direct pleiotropic actions on the vascular wall and myocardium
Hydration needs should be individualized based on body size, activity level, climate, and medical conditionspatients with heart failure or kidney disease should follow their healthcare provider's specific fluid intake recommendations